Adjunctive Atropine During Ketamine Sedation
Keywords
Abstract
Description
The degree of secretion was significantly less in the atropine group compared with the control group at the end of the procedure (VAS score: 16.5 ± 9.9 vs. 27.0 ± 15.9, atropine vs. control, p = 0.00). The change in the degree of secretion between the start and end of the procedure was significantly greater in the atropine group than in the control group (p = 0.00) (Fig. 2). However, the frequency of hypersalivation as predefined (VAS score ≥50) did not differ between the groups (p = 0.06).
The only complication that differed significantly between the two groups was tachycardia (p > 0.05). Complications such as aspiration, laryngospasm, and apnea were not documented in the hospital. There were fewer interventions for hypersalivation in the atropine group, but the difference was not significant (p > 0.05). As interventions, O2 administration and endotracheal intubation were not needed. After discharge, the control patients tended to have more complaints of nausea, vomiting, and ataxia, although the difference was not significant (p > 0.05) Heart rate was increased significantly in the atropine group (p = 0.00). The frequency of tachycardia according to patient age was also significantly higher in the atropine group than in the control group (p = 0.00)
Dates
| Last Verified: | 07/31/2012 |
| First Submitted: | 01/31/2009 |
| Estimated Enrollment Submitted: | 01/31/2009 |
| First Posted: | 02/02/2009 |
| Last Update Submitted: | 08/02/2012 |
| Last Update Posted: | 08/05/2012 |
| Actual Study Start Date: | 07/31/2008 |
| Estimated Primary Completion Date: | 11/30/2010 |
| Estimated Study Completion Date: | 11/30/2010 |
Condition or disease
Intervention/treatment
Drug: Atropine
Phase
Arm Groups
| Arm | Intervention/treatment |
|---|---|
| Experimental: Atropine Atropine 0.01mg/kg IV | |
| Placebo Comparator: Normal saline Same volume of atropine |
Eligibility Criteria
| Ages Eligible for Study | 12 Months To 12 Months |
| Sexes Eligible for Study | All |
| Accepts Healthy Volunteers | Yes |
| Criteria | Inclusion Criteria: - Pediatric lacerated patients Exclusion Criteria: - Contraindication of ketamine or atropine |
Outcome
Primary Outcome Measures
1. Hypersalivation(VAS) [During procedure]
Secondary Outcome Measures
1. Sedation scale [before, during procedure, before discharge]
2. Pain scale [before, during procedure, before discharge]
3. Complication [during procedure and bedore discharge and 1day after discharge]
4. Satisfaction of parents and clinicians [before discharge]
